The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer

European Urology

Volumn 44, Issue 2, 2003, Pages 209-214

  Van Andel, G ^a,b   Kurth, K H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

Androgen deprivation; Hormonal treatment; Prostate cancer; Quality of life

Indexed keywords

HORMONE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0042268032     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00208-2     Document Type: Article

References (20)

1. Kramolowsky EV. The value of testosterone deprivation in stage DI carcinoma of the prostate. J Urol 1988;139:1242-4.
2. van den Ouden D, Tribukait B, Blom JH, Fossa SD, Kurth KH, ten Kate FJ, et al. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. The European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1993;150:400-6.
3. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
4. Granfors T, Damber JE, Bergh A, Landstrom M, Lofroth PO, Widmark A. Combined castration and fractionated radiotherapy in an experimental prostatic adenocarcinoma. Int J Radiat Oncol Biol Phys 1997;39:1031-6.
5. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8.
6. Zincke H, Utz DC, Thule PM, Taylor WF. Treatment options for patients with stage D1 (T0-3, N1-2, MO) adenocarcinoma of prostate. Urology 1987;30:307-15.
7. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997;79:235-46.
8. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
9. Selby PJ, Chapman JA, Etazadi-Amoli J, Dalley D, Boyd NF. The development of a method for assessing the quality of life of cancer patients. Br J Cancer 1984;50:13-22.
10. Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549-57.
11. Derogatis LR, Kourlesis SM. An approach to evaluation of sexual problems in the cancer patient. CA Cancer J Clin 1981;31:46-50.
12. Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane. Database. Syst Rev 2002;CD003506.
13. Chapman GB, Elstein AS, Kuzel TM, Sharifi R, Nadler RB, Andrews A, et al. Prostate cancer patients' utilities for health states: how it looks depends on where you stand. Med Decis Making 1998;18:278-86.
14. Chapman GB, Elstein AS, Kuzel TM, Nadler RB, Sharifi R, Bennett CL. A multi-attribute model of prostate cancer patient's preferences for health states. Qual Life Res 1999;8:171-80.
15. Litwin MS, Fitzpatrick JM, Fossa SD, Newling DW. Defining an international research agenda for quality of life in men with prostate cancer. Prostate 1999;41:58-67.
16. Herr HW, O'Sullivan M. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J Urol 2000;163:1743-6.
17. Stone P, Hardy J, Huddart R, A'Hern R, Richards M. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000;36:1134-41.
18. Herr HW, Komblith AB, Ofman U. A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 1993;71:1143-50.
19. Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002;94:430-7.
20. Knight SJ, Chmiel JS, Kuzel T, Sharp L, Albers M, Fine R, et al. Quality of life in metastatic prostate cancer among men of lower socioeconomic status: feasibility and criterion related validity of 3 measures. J Urol 1998;160:1765-9.